Skip to content
The practice of making drug makers give rebates to payers encourages Medicare Part D insurers to steer patients away from generic drugs that cost […]
HHS probe: Insurer PBMs pocket rebates as patients, taxpayers pay more Read More »
Congress needs to ensure the smooth continuation of two federal programs that provide seed funding for small, innovative businesses, according to a host of
SBIR/STTR seed-funding programs running out of money – and Congress needs to act Read More »
The patchwork of state regulations regarding Medicaid coverage for new, innovative treatments can create barriers for patients seeking access to the most advanced therapies,
Report: State Medicaid policies can interfere with access to new treatments Read More »
What is the value of a treatment? As of July, the U.S. government has given out close to 600 million doses of COVID-19 vaccines
Efforts at value-based care focus on patients’ needs Read More »
In the battle against the current monkeypox outbreak, humanity seems to be ahead of where we were when COVID-19 first appeared. Smallpox solutions already
We have monkeypox treatments – but must act fast Read More »
The draft of the next Food and Drug Administration (FDA) user fee agreement currently making its way through Congress was developed with close cooperation
PDUFA panelists praise FDA’s cooperation on setting drug approval process Read More »
If new restrictions are placed on the FDA’s Accelerated Approval pathway, a program to speed market access for drugs addressing serious conditions, as many
Report shows Accelerated Approval’s value in money and lives Read More »
The Food and Drug Administration’s greater reliance on digital tools during the pandemic showed the agency how these tools could be used to expand
FDA officials see benefits of pandemic-driven digitalization Read More »
Asked what this pandemic taught us that will help us prepare for the next one, a panel of experts mentioned the need to improve
COVID lessons on manufacturing, distribution, regulation Read More »
One of the key lessons of the COVID-19 pandemic has been the need to strengthen government support for biotechnology, with direct funding but also
Top officials share a key COVID lesson: Governments must support biotech Read More »
